Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia
Expert Review of Pharmacoeconomics & Outcomes Research · 05.11.2026 · 1-10
DOI: 10.1080/14737167.2026.2760016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, online erschienen am 05.11.2026. Verfasst von Ryeska Fajar Respaty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Adding milrinone to dobutamine (dobutamine-milrinone escalation) in cardiogenic shock (CS) is reimbursed for a limited duration under Indonesia's national health insurance, but its cost structure is poorly characterized. This study quantified direct medical charges associated with escalation and the contribution of drug acquisition. RESEARCH DESIGN AND METHODS: Retrospective cohort of 76 adult CS survivors (20 escalation, 56 dobutamine monotherapy) at Indonesia's national cardiovascular referral center, 2020-2024. Covariate Balancing Propensity Score-based inverse probability of treatment weighting, using pre-treatment covariates, estimated adjusted cost ratios (CR) for intensive cardiovascular care unit (ICVCU) and total hospital costs from institutional billing records. RESULTS: Escalation was associated with higher ICVCU costs (CR 2.711; 95% CI 1.912-3.844; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
- Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
- Department of Cardiology, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
Zitieren
APA
Fajar Respaty, R., Purna Sari, S., & Widyantoro, B. (2026). Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia. Expert Review of Pharmacoeconomics & Outcomes Research, 1-10. https://doi.org/10.1080/14737167.2026.2760016
Vancouver
Fajar Respaty R, Purna Sari S, Widyantoro B. Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia. Expert Review of Pharmacoeconomics & Outcomes Research. 2026:1-10. doi:10.1080/14737167.2026.2760016
BibTeX
@article{FajarRespaty2026,
author = {Fajar Respaty, Ryeska and Purna Sari, Santi and Widyantoro, Bambang},
title = {Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2026},
pages = {1--10},
doi = {10.1080/14737167.2026.2760016}
}
EUVIMED